Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux Opportunity In Japan Has Been Overlooked By Investors

This article was originally published in PharmAsia News

Executive Summary

ImClone said July 16 that its oncologic Erbitux (cetuximab) has been approved in Japan for treatment of advanced colon cancer. Under an existing deal, Merck KGaA will receive 50 percent of profits from sales in Japan, and ImClone and Bristol-Myers Squibb will receive 25 percent each. An application for Erbitux in earlier-stage colon cancer is pending with Japanese regulators. Several analysts say that the Japanese market is an opportunity for Erbitux that has been overlooked by investors. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel